'UTHR' Insider Jackpot… CEO and CFO Realize Tens of Millions After Exercising Stock Options at High Share Price

On March 20 and 23, 2026, at United Therapeutics Corporation (NASDAQ: UTHR), founder and CEO Martine A. Rothblatt and CFO James Edgemond each exercised stock options and sold the resulting common shares at market prices, realizing gains of approximately $36 million to the mid-$50 million range per transaction. These trades were executed under Rule 10b5-1 trading plans established at the end of 2025. While Rothblatt’s direct holdings decreased slightly, she still maintains indirect ownership of over 650,000 shares through family trusts and other entities, and Edgemond likewise retains a substantial stake valued in the hundreds of millions of Korean won. The dollar value of the transactions amounted to roughly $5 million per CEO trade and $5.2–$5.3 million per CFO trade, totaling about $15 million (approximately KRW 200 billion).

In early March, the company announced that its investigational pulmonary arterial hypertension (PAH) therapy ralinepag reduced the risk of clinical worsening by 55% in the pivotal ADVANCE OUTCOMES trial, and plans to submit a new drug application to the U.S. Food and Drug Administration (FDA) in the second half of 2026. Additionally, on March 9, 2026, United Therapeutics’ board approved a share repurchase program of up to $2 billion (approximately KRW 2.7 trillion), alongside authorizing accelerated repurchases over the next year and securing additional funds for future buybacks as part of its shareholder return strategy.

United Therapeutics Corporation, based in Maryland and North Carolina, is a biotechnology company specializing in therapies for rare pulmonary arterial hypertension and organ manufacturing technologies for transplantation. Its key marketed products include the PAH treatments Remodulin and Tyvaso. Founder Martine Rothblatt, originally an entrepreneur behind SiriusXM satellite radio, entered PAH research and drug development in the 1990s following her daughter’s diagnosis with a rare disease.